Cabometyx in Combination with Nivolumab Demonstrates Survival Benefits for First-Line Treatment of Advanced Kidney Cancer

(Boursier.com) — Ipsen announces results over a minimum of three years – with a median follow-up of 44 months – from the Phase III CheckMate -9ER trial. Data from the study demonstrates that Cabometyx (cabozantinib) in combination with nivolumab improves three-year survival and response rate in the first-line treatment of aRCC, compared to sunitinib. These results will be presented at the ASCO GU to be held from February 16 to 18, 2023.

RCC is the most common type of kidney cancer and accounts for about 90% of cases. If detected at an early stage, the 5-year survival rate is high, but for people with advanced or late-stage metastatic RCC, the survival rate is much lower, rising to about 12%.

“Despite advances in science and medicine, patients with metastatic renal cell carcinoma, especially those considered to be at higher risk, need treatment options that will sustainably extend their lifespan,” said Mauricio Burotto, MD, Medical Director of Bradford Hill Clinical Research Center, Santiago, Chile. “With new results from the CheckMate -9ER trial, we have now demonstrated that nivolumab in combination with cabozantinib can sustainably improve survival and maintain response benefits in patients compared to sunitinib over more three years, regardless of risk classification.These data also reinforce the importance of the TKI-immunotherapy regimen for patients and demonstrate the potential of this treatment to change survival expectations for people with this complex cancer. “

In the CheckMate -9ER trial, overall survival (OS) benefits were maintained over a three-year follow-up period. Median OS is significantly higher in patients taking Cabometyx in combination with nivolumab compared to sunitinib, at 49.5 versus 35.5 months respectively [rapport de risque (HR) 0,70 [intervalle de confiance (IC) 95% 0,56-0,87], p = 0.0014)]demonstrating a 30% reduction in the risk of death. Additionally, median OS improved from 11.8 months since the previous data collection to 32.9 months median follow-up.